Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Overcoming Barriers in the Implementation of Programs for Breast and Cervical Cancers in Cali, Colombia: A Pilot Model.

Sardi A, Orozco-Urdaneta M, Velez-Mejia C, Perez-Bustos AH, Munoz-Zuluaga C, El-Sharkawy F, Parra-Lara LG, Córdoba P, Gallo D, Sittig M, King MC, Nieroda C, Zambrano-Vera K, Singer J.

J Glob Oncol. 2019 Jul;5:1-9. doi: 10.1200/JGO.19.00054.

2.

Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.

Munoz-Zuluaga CA, King MC, Ledakis P, Gushchin V, Sittig M, Nieroda C, Zambrano-Vera K, Sardi A.

Eur J Surg Oncol. 2019 Sep;45(9):1598-1606. doi: 10.1016/j.ejso.2019.05.008. Epub 2019 May 9.

PMID:
31109821
3.

Selection and Characteristics of Patients with Peritoneal Dissemination from Appendiceal Cancer with Exceptional/Poor Survival After CRS/HIPEC.

Munoz-Zuluaga C, King MC, Sardi A, Ledakis P, Sittig M, Nieroda C, MacDonald R, Gushchin V.

Ann Surg Oncol. 2019 Jul;26(7):2268-2275. doi: 10.1245/s10434-019-07374-z. Epub 2019 Apr 30.

PMID:
31041628
4.

Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment.

Merrell DS, McAvoy TJ, King MC, Sittig M, Millar EV, Nieroda C, Metcalf JL, Blum FC, Testerman TL, Sardi A.

Eur J Surg Oncol. 2019 Sep;45(9):1723-1726. doi: 10.1016/j.ejso.2019.01.223. Epub 2019 Jan 30.

PMID:
30770164
5.

Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.

Sipok A, Sardi A, Nieroda C, King MC, Sittig M, Gushchin V.

Int J Surg Oncol. 2018 Dec 13;2018:1920276. doi: 10.1155/2018/1920276. eCollection 2018.

6.

Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Munoz-Zuluaga C, Sardi A, King MC, Nieroda C, Sittig M, MacDonald R, Gushchin V.

Ann Surg Oncol. 2019 Feb;26(2):473-481. doi: 10.1245/s10434-018-7007-3. Epub 2018 Dec 6.

PMID:
30523470
7.

Misdiagnosis of a hidden cause of hypertension: a case report.

de Lima A, El-Sharkawy F, Nieroda C, Sardi A.

Br J Gen Pract. 2017 Dec;67(665):578-579. doi: 10.3399/bjgp17X693869. No abstract available. Erratum in: Br J Gen Pract. 2018 Jan;68(666):15.

8.

External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix.

Milovanov V, Sardi A, Aydin N, Nieroda C, Sittig M, Gushchin V.

Ann Surg Oncol. 2017 Jul;24(7):1783-1786. doi: 10.1245/s10434-017-5794-6. Epub 2017 Mar 17.

PMID:
28315061
9.

Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.

Aydin N, Sardi A, Milovanov V, Nieroda C, Sittig M, Nunez MF, Jimenez W, Gushchin V.

Am Surg. 2015 Dec;81(12):1253-9.

PMID:
26736164
10.

The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).

Milovanov V, Sardi A, Studeman K, Nieroda C, Sittig M, Gushchin V.

Ann Surg Oncol. 2016 Jun;23(6):1928-33. doi: 10.1245/s10434-015-5047-5. Epub 2015 Dec 29.

PMID:
26714951
11.

Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin.

Milovanov V, Sardi A, Aydin N, Nieroda C, Sittig M, Nunez M, Gushchin V.

Eur J Surg Oncol. 2015 Jul;41(7):881-5. doi: 10.1016/j.ejso.2015.02.016. Epub 2015 Apr 13.

PMID:
25899982
12.

Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).

Milovanov V, Sardi A, Ledakis P, Aydin N, Nieroda C, Sittig M, Nunez M, Gushchin V.

Eur J Surg Oncol. 2015 May;41(5):707-12. doi: 10.1016/j.ejso.2015.01.005. Epub 2015 Jan 17.

PMID:
25633641
13.

Port-site metastases is an independent prognostic factor in patients with peritoneal carcinomatosis.

Nunez MF, Sardi A, Jimenez W, Nieroda C, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V.

Ann Surg Oncol. 2015 Apr;22(4):1267-73. doi: 10.1245/s10434-014-4136-1. Epub 2014 Oct 16.

PMID:
25319578
14.

Morbidity of the abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Nunez MF, Sardi A, Nieroda C, Jimenez W, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V.

Ann Surg Oncol. 2015 May;22(5):1658-63. doi: 10.1245/s10434-014-4075-x. Epub 2014 Sep 23.

PMID:
25245127
15.

Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Jimenez W, Sardi A, Nieroda C, Sittig M, Milovanov V, Nunez M, Aydin N, Gushchin V.

Ann Surg Oncol. 2014 Dec;21(13):4218-25. doi: 10.1245/s10434-014-3869-1. Epub 2014 Jul 2.

PMID:
24986239
16.

Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Sardi A, Jimenez W, Nieroda C, Sittig M, Shankar S, Gushchin V.

Ann Surg Oncol. 2014 Mar;21(3):908-14. doi: 10.1245/s10434-013-3407-6. Epub 2013 Nov 26.

PMID:
24276642
17.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent high-grade uterine sarcoma with peritoneal dissemination.

Jimenez WA, Sardi A, Nieroda C, Gushchin V.

Am J Obstet Gynecol. 2014 Mar;210(3):259.e1-8. doi: 10.1016/j.ajog.2013.11.002. Epub 2013 Nov 7.

PMID:
24211479
18.

The role of VEGFR-2 expression in outcomes and survival of patients with peritoneal carcinomatosis from appendiceal cancer.

Jimenez WA, Sardi A, Ledakis P, Nieroda C, Sittig M, Gushchin V.

Eur J Surg Oncol. 2013 Dec;39(12):1415-22. doi: 10.1016/j.ejso.2013.08.032. Epub 2013 Sep 12.

PMID:
24075030
19.

Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.

Sardi A, Jimenez WA, Nieroda C, Sittig M, Macdonald R, Gushchin V.

Eur J Surg Oncol. 2013 Nov;39(11):1207-13. doi: 10.1016/j.ejso.2013.08.017. Epub 2013 Sep 2.

PMID:
24007834
20.

A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.

Gilbreath JJ, Semino-Mora C, Friedline CJ, Liu H, Bodi KL, McAvoy TJ, Francis J, Nieroda C, Sardi A, Dubois A, Lazinski DW, Camilli A, Testerman TL, Merrell DS.

Orphanet J Rare Dis. 2013 Jul 12;8:105. doi: 10.1186/1750-1172-8-105.

21.

Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution.

Semino-Mora C, Testerman TL, Liu H, Whitmire JM, Studeman K, Jia Y, McAvoy TJ, Francis J, Nieroda C, Sardi A, Merrell DS, Dubois A.

Clin Cancer Res. 2013 Jul 15;19(14):3966-76. doi: 10.1158/1078-0432.CCR-13-0616. Epub 2013 Jun 6.

22.

Delay of cytoreductive surgery and heated intraperitoneal chemotherapy in patients with appendiceal neoplasm.

El Halabi H, MacDonald R, Studeman K, Francis J, Nieroda C, Gushchin V, Sardi A.

Am Surg. 2012 Jul;78(7):745-8.

PMID:
22748531
23.

Prognostic significance of lymph node metastases in patients with high-grade appendiceal cancer.

Halabi HE, Gushchin V, Francis J, Athas N, Macdonald R, Nieroda C, Studeman K, Sardi A.

Ann Surg Oncol. 2012 Jan;19(1):122-5. doi: 10.1245/s10434-011-1903-0. Epub 2011 Jul 12.

PMID:
21748246
24.

The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.

El Halabi H, Gushchin V, Francis J, Athas N, Macdonald R, Nieroda C, Studeman K, Sardi A.

Ann Surg Oncol. 2012 Jan;19(1):110-4. doi: 10.1245/s10434-011-1840-y. Epub 2011 Jun 24.

PMID:
21701929
25.

Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.

Ross A, Sardi A, Nieroda C, Merriman B, Gushchin V.

Eur J Surg Oncol. 2010 Aug;36(8):772-6. doi: 10.1016/j.ejso.2010.05.024. Epub 2010 Jun 18.

PMID:
20561764
26.

Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.

Omohwo C, Nieroda CA, Studeman KD, Thieme H, Kostuik P, Ross AS, Holter DR, Gushchin V, Merriman B, Sardi A.

J Am Coll Surg. 2009 Sep;209(3):308-12. doi: 10.1016/j.jamcollsurg.2009.04.019. Epub 2009 Jul 9.

PMID:
19717034
27.

Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.

Semino-Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, Sardi A, Dubois A.

Ann Surg Oncol. 2008 May;15(5):1414-23. doi: 10.1245/s10434-007-9778-9. Epub 2008 Feb 26.

28.

Radioimmunoguided-intraoperative radiation therapy in colorectal carcinoma: a new technique to precisely define the clinical target volume.

Nag S, Martinez-Monge R, Nieroda C, Martin E Jr.

Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):133-7.

PMID:
10219806
29.

Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver.

Martinez-Monge R, Nag S, Nieroda CA, Martin EW.

Cancer. 1999 Mar 15;85(6):1218-25.

PMID:
10189125
30.

Staging of colorectal cancer: biology vs. morphology.

Arnold MW, Young DM, Hitchcock CL, Barberá-Guillem E, Nieroda C, Martin EW Jr.

Dis Colon Rectum. 1998 Dec;41(12):1482-7.

PMID:
9860326
31.

Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: radioimmunoguided surgery and antigen augmentation.

Roselli M, Buonomo O, Piazza A, Guadagni F, Vecchione A, Brunetti E, Cipriani C, Amadei G, Nieroda C, Greiner JW, Casciani CU.

Semin Surg Oncol. 1998 Dec;15(4):254-62. Review.

PMID:
9829383
32.

Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.

Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2439-49.

33.

[Lymphadenectomy in colorectal carcinoma].

Nieroda CA, Arnold MW, Barbera-Guillem E, Martin EW.

Chirurg. 1998 Jul;69(7):717-24. Review. German.

PMID:
9738216
34.

Intraoperative high dose rate brachytherapy in recurrent or metastatic colorectal carcinoma.

Nag S, Martinez-Monge R, Mills J, Bauer C, Grecula J, Nieroda C, Martin E.

Ann Surg Oncol. 1998 Jan-Feb;5(1):16-22.

PMID:
9524702
35.

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.

Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY.

J Natl Cancer Inst. 1997 Feb 19;89(4):293-300.

PMID:
9048833
36.

Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine.

Greiner JW, Guadagni F, Roselli M, Nieroda CA.

Anticancer Res. 1996 Jul-Aug;16(4B):2129-33. Review.

PMID:
8694532
37.

Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN-gamma in short-term human mammary carcinoma cell cultures.

Sgagias MK, Nieroda C, Yannelli JR, Cowan KH, Danforth DN Jr.

Cancer Biother Radiopharm. 1996 Jun;11(3):177-85.

PMID:
10851535
38.

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.

Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J.

J Natl Cancer Inst. 1995 Jul 5;87(13):982-90.

PMID:
7629885
39.

Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.

Qi CF, Nieroda C, De Filippi R, Greiner JW, Correale P, Schlom J, Tsang KY.

Immunol Lett. 1995 Jul-Aug;47(1-2):15-24.

PMID:
8537095
40.
41.

Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.

Yamaue H, Kashmiri SV, De Filippi R, Nieroda C, Yannelli JR, Tsang KY, Schlom J.

J Immunother Emphasis Tumor Immunol. 1994 Nov;16(4):262-74.

PMID:
7881635
42.

Differential effects of recombinant interferon-alpha and 5-fluorouracil against colon cancer cells or against peripheral blood mononuclear cells.

De Filippi R, Prete SP, Giuliani A, Silvi E, Yamaue H, Nieroda CA, Greiner JW, De Vecchis L, Bonmassar E.

Anticancer Res. 1994 Sep-Oct;14(5A):1767-73.

PMID:
7847809
43.

Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma.

Greiner JW, Guadagni F, Roselli M, Ullmann CD, Nieroda C, Schlom J.

Dis Colon Rectum. 1994 Feb;37(2 Suppl):S100-5.

PMID:
8313780
44.

Biological response modifiers as adjuvants in monoclonal antibody-based treatment (review).

Guadagni F, Roselli M, Nieroda C, Dansky-Ullmann G, Schlom J, Greiner JW.

In Vivo. 1993 Nov-Dec;7(6B):591-9. Review.

PMID:
8193280
45.

Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression.

Tsang KY, Kashmiri SV, Qi CF, Nieroda C, Calvo B, De Filippi R, Greiner JW, Primus FJ, Schlom J.

Immunol Lett. 1993 May;36(2):179-85.

PMID:
8102353
46.

A human T cell line engineered to secrete chimeric monoclonal antibody.

Tsang KY, Kashmiri SV, De Filippi R, Qi CF, Calvo B, Shu L, Nieroda CA, Greiner JW, Schlom J.

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):143-52.

PMID:
8471589
47.

Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.

Greiner JW, Ullmann CD, Nieroda C, Qi CF, Eggensperger D, Shimada S, Steinberg SM, Schlom J.

Cancer Res. 1993 Feb 1;53(3):600-8.

48.

Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer.

Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW Jr.

Cancer Detect Prev. 1991;15(3):225-9.

PMID:
2059962
49.

Low-dose cyclophosphamide enhances helper-to-non-helper ratios.

Sardi A, Agnone C, Anderson G, Bolton JS, Sundgaard-Riise K, Nieroda C, Minton JP.

Cancer Detect Prev. 1991;15(3):217-24.

PMID:
1829393
50.

Gamma-detecting probe and autoradiographic studies of radiolabeled antibody B72.3 in CX-1 colon xenografts.

Sampsel JW, Hinkle G, Nieroda C, Ignaszewski J, Thurston M, Martin EW.

J Surg Oncol. 1990 Dec;45(4):242-9.

PMID:
2250474

Supplemental Content

Loading ...
Support Center